Data for Action March 2022, Issue 5
Il est plus essentiel que jamais d’assurer un accès équitable aux vaccins contre la COVID-19 pour faire face à l’évolution de la pandémie. Si le virus est éliminé dans certaines régions du monde alors qu’il se propage largement dans d’autres régions, nous courons tous le risque que ...des souches plus fortes apparaissent. Nous ne sommes à l’abri que si tout le monde est à l’abri. Grâce aux notes explicatives de l’OMS sur les vaccins, en savoir plus sur les vaccins, sur leur fonctionnement et sur la façon dont ils sont fabriqués pour en garantir l’innocuité et y permettre un accès équitable.
more
The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD)
Data from the 2011 Ethiopia Demographic and Health Survey
COVID-19 Vaccines: 1 Safety Surveillance 2 Manual
While there is no indication that pregnant women have an increased susceptibility to infection with SARS-CoV-2, there is evidence that pregnancy may increase the risk of severe illness and mortality from COVID-19 disease in comparison with non-pregn...ant women of reproductive age. As seen with non-pregnant women, a high proportion of pregnant women have asymptomatic SARS-CoV-2 infection and severe disease is associated with recognized medical (e.g., high body-mass index (BMI), diabetes, pre-existing pulmonary or cardiac conditions) and social (e.g., social deprivation, ethnicity) risk factors. Pregnant women with symptomatic COVID-19 appear to have an increased risk of intensive care unit admission, mechanical ventilation and death in comparison with non-pregnant women of reproductive age, although the absolute risks remain low. COVID-19 may increase the risk of preterm birth, compared with pregnant women without COVID-19, although the evidence is inconclusive.
more
The Committee examined the clinical development of Ebola virus vaccines and conducted an inventory of available data on their safety. It also reviewed 3 generic issues: updating a global strategy on vaccine safety, use of a network of distributed data ... to monitor the safety of vaccines and case studies of communication about the safety of human papillomavirus (HPV) vaccines.
Weekly epidemiological record/Relevé épidémiologique hebdomadaire 12 JULY 2019, 94th YEAR / 12 JUILLET 2019, 94e ANNÉENo 28, 2019, 94, 309–316
more
Die Johanniter haben im Rahmen ihrer Aktivitäten im Bereich Flüchtlingshilfe und Integration allgemeine, niedrigschwellige Informationen zum Thema Corona-Impfung in verschiedenen Sprachen bereitgestellt. Diese dienen als Ergänzung zu den offiziellen Informationsmaterialien der Bundeszentrale für... gesundheitliche Aufklärung u.a. Die Informationsblätter wurden in Zusammenarbeit mit dem Ethno-medizinischen Zentrum e.V. Hannover übersetzt und werden bei Bedarf aktualisiert.
Die Informationsblätter sind in zahlreichen Sprachen verfügbar
more
OpenWHO is WHO’s new, interactive, web-based platform that offers online courses to people preparing to work in epidemics, pandemics and health emergencies or already doing so.
The OpenWHO platform delivers WHO’s and partners’ expertise closer to where it is needed and provides information ...in user-friendly formats for frontline responders and decision-makers. The platform is managed by WHO’s Department for Infectious Hazards Management, in Geneva, Switzerland.
Users take part in a worldwide, social learning network that is based on interactive, online courses and materials covering a variety of subjects. OpenWHO also serves as a forum for the fast sharing of public health expertise and in-depth discussion and feedback on key issues.
Accessed 6 March 2019.
more
La evidencia disponible a nivel internacional sobre el uso de un segundo refuerzo muestra una mayor duración de la respuesta inmune y una disminución de la internación y la mortalidad por COVID 19 en la población de adultos mayores y huéspedes inmunocomprometidos. Por otra parte, el personal de... salud se beneficiaría considerando el mayor riesgo de exposición y la caída de la respuesta inmune con el tiempo. En base a lo señalado previamente se recomienda incorporar y
priorizar un segundo refuerzo al esquema de vacunación contra la COVID-19 del:
- Personal de salud independientemente de la edad
- Personas de 50 años o mayores
- Personas de 12 años o más con inmunocompromiso
A la vez, se progresará de manera escalonada y simultánea con la vacunación de segundo refuerzo del:
- Personal estratégico
- Personas de 18 a 49 años con factores de riesgo
Continuando en la estrategia de segundo refuerzo todas las personas a partir de los 18 años. Las personas gestantes con indicación de segundo refuerzo, se recomienda vacunas de plataforma de ARNm (Pfizer-BioNTech o Moderna)
more